Hydroxychloroquine occupies an unusual position in modern rheumatology: a decades-old drug, cheap and unglamorous, that remains a cornerstone of care for systemic lupus erythematosus and continues to hold a defined, if more limited, place in rheumatoid arthritis. This article sets out what the actual clinical evidence shows for each condition, how strong that evidence is, what the drug's known risks are, and how patients and physicians weigh those considerations together. The aim is not to promote or dismiss the drug but to describe, plainly and with sources, what has actually been demonstrated.

Where the Drug Comes From and How It Works

Hydroxychloroquine is a synthetic derivative of chloroquine, which itself descends from quinine, the alkaloid extracted from the bark of the cinchona tree native to South America. Indigenous peoples of the Andes used cinchona bark for fevers long before European chemists isolated its active compound in the nineteenth century. It is worth pausing on that lineage: a molecule refined for malaria, drawn originally from a tree bark, turned out decades later to modulate the human immune system in ways still not fully mapped. That a compound from the created world could serve two such different medical purposes is a reminder of how much remains to be understood about the ordinary materials of the earth.

Mechanistically, hydroxychloroquine is a weak base that concentrates inside acidic cellular compartments called lysosomes, raising their pH. This interferes with antigen processing by immune cells and dampens signaling through toll-like receptors 7 and 9, which detect nucleic acids and drive much of the abnormal immune activation seen in lupus. It also reduces production of inflammatory cytokines such as interferon-alpha and tumor necrosis factor. These effects are well established in laboratory and cell-based studies; the clinical consequence is a broad, gradual dampening of immune overactivity rather than the rapid, targeted suppression seen with biologic drugs.

The Evidence in Lupus: A Genuinely Foundational Drug

The case for hydroxychloroquine in systemic lupus erythematosus rests on some of the more durable evidence in rheumatology. The pivotal trial is the Canadian Hydroxychloroquine Study Group's randomized, double-blind withdrawal trial, published in the New England Journal of Medicine in 1991. Patients with stable lupus already taking the drug were randomized to continue it or switch to placebo. Those withdrawn from hydroxychloroquine flared significantly more often and more severely over the following months, providing direct randomized evidence that the drug actively suppresses disease activity rather than simply correlating with milder disease.

Since then, the evidence base has grown mainly through large observational cohorts, most notably the Hopkins Lupus Cohort led by Dr. Michelle Petri at Johns Hopkins University, which has followed lupus patients prospectively for decades. Analyses from that cohort and others have associated hydroxychloroquine use with:

These survival and organ-protection findings are observational, not from randomized trials, so they cannot prove causation with the same certainty as the 1991 withdrawal study. Patients who tolerate and adhere to hydroxychloroquine over years may differ in other ways from those who do not. Still, the consistency of the association across multiple independent cohorts, combined with the randomized withdrawal data confirming a direct disease-suppressing effect, is why hydroxychloroquine is recommended by rheumatology bodies including the American College of Rheumatology as a baseline therapy for essentially all lupus patients who can tolerate it, regardless of how severe their disease is at a given moment.

The Evidence in Rheumatoid Arthritis: A More Modest, Supporting Role

The evidence in rheumatoid arthritis is real but considerably less compelling than in lupus, and this distinction matters for anyone weighing the drug's use. Older randomized controlled trials from the 1980s and 1990s, including work summarized in Cochrane systematic reviews, showed that hydroxychloroquine produces modest improvement in joint pain, swelling, and morning stiffness compared with placebo. It is, however, considered one of the least potent conventional disease-modifying antirheumatic drugs (DMARDs). It does not reliably slow radiographic joint damage the way methotrexate does, and as monotherapy it is generally insufficient for patients with moderate to severe disease.

Its more established role in RA is as part of combination therapy. Trials such as the Finnish FIN-RACo study in the 1990s tested combinations of methotrexate, sulfasalazine, and hydroxychloroquine against methotrexate alone in early RA and found combination therapy produced better remission rates. Hydroxychloroquine is also sometimes added for its favorable effect on lipid and glucose parameters in patients who need additional metabolic support, and for its relatively benign side-effect profile compared with other DMARDs, which makes it a reasonable component in a multi-drug regimen or a bridge therapy for mild disease. It is not, on current evidence, appropriate to view hydroxychloroquine as a primary treatment for RA when disease activity is significant; guidelines from the American College of Rheumatology reserve it mainly for very mild disease or as an adjunct.

Safety, Monitoring, and the Retinopathy Question

The most clinically important long-term risk of hydroxychloroquine is retinopathy, a slowly progressive and potentially irreversible damage to the retina. A widely cited study by Melles and Marmor, published in JAMA Ophthalmology in 2014 using data from a large Kaiser Permanente population, found that retinopathy risk was strongly dependent on daily dose relative to body weight and on duration of use, with risk rising substantially after five to ten years of continuous use, particularly at higher weight-based doses. This finding reshaped clinical practice.

The American Academy of Ophthalmology revised its screening guidelines in 2016 in direct response to this and related data. Current practice generally involves:

Other known effects include occasional gastrointestinal upset, skin pigment changes, and, rarely, cardiac conduction effects or muscle toxicity with very long-term use. These are uncommon but are a legitimate part of the informed-consent conversation a patient should have with their physician before starting therapy and at intervals afterward. Responsible use of this drug depends on that ongoing dialogue and on patients keeping their monitoring appointments, which is itself an act of taking ownership of one's own long-term health rather than treating a prescription as a one-time decision.

Pregnancy, Family Planning, and the Case for Continuation

Because lupus disproportionately affects women of childbearing age, and because lupus flares during pregnancy carry real risk to both mother and child, the safety of hydroxychloroquine in pregnancy has been studied specifically and carefully. Multiple observational studies, including data drawn from the PROMISSE study coordinated across several American academic medical centers, have not found an increased risk of birth defects associated with hydroxychloroquine use, and discontinuing the drug during pregnancy is associated with a higher risk of lupus flare. For this reason, the American College of Rheumatology and equivalent bodies in Europe recommend that most women with lupus continue hydroxychloroquine throughout pregnancy and while breastfeeding, a notable case where protecting the mother's health and protecting the developing child point in the same direction rather than in tension. This should never be read as blanket advice, however; every pregnancy and every case of lupus is different, and the decision belongs to the patient and her own physician, weighing her specific history.

Weighing the Evidence Honestly

Put plainly: the evidence for hydroxychloroquine in lupus is strong, built on a genuine randomized trial and reinforced by decades of consistent observational data across independent cohorts, and it is treated as standard of care for good reason. The evidence in rheumatoid arthritis is real but modest, best understood as a supporting player in combination regimens or a reasonable option for mild disease rather than a frontline treatment for significant joint inflammation. The drug's principal long-term risk, retinal toxicity, is well characterized and manageable with weight-based dosing and scheduled eye examinations, provided patients and clinicians actually follow through on that monitoring. None of this evidence supports using the drug outside these established indications without a physician's specific guidance, and patients considering it, or already taking it, do well to ask their own rheumatologist directly what the data shows for their particular case rather than relying on general summaries, however carefully researched.